Apellis Pharmaceuticals, Inc. earned $0.20 per diluted share in fiscal year 2025. This represents an increase of 112.5% from the prior fiscal year. Over the trailing 12 months, Q2 FY2025 through Q1 FY2026, the same line adds up to $1.04 per diluted share. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Apellis Pharmaceuticals, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)$0.20
YoY+112.5%
Source SEC Filings (10-K/10-Q)Latest period Q1 FY2026, ended Mar 31, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
APLS EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Apellis Pharmaceuticals, Inc.'s diluted earnings per share in fiscal year 2025?
Apellis Pharmaceuticals, Inc. earned $0.20 per diluted share in fiscal year 2025.
How fast is Apellis Pharmaceuticals, Inc.'s diluted earnings per share growing?
Apellis Pharmaceuticals, Inc. (APLS) diluted earnings per share rose by 112.5% year over year, from -$1.60 to $0.20 in fiscal year 2025.
What is Apellis Pharmaceuticals, Inc.'s diluted earnings per share over the last twelve months?
Apellis Pharmaceuticals, Inc. (APLS) reported $1.04 per diluted share over the trailing 12 months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.
What was Apellis Pharmaceuticals, Inc.'s diluted earnings per share in the most recent quarter?
Apellis Pharmaceuticals, Inc. (APLS) reported $0.15 in diluted earnings per share in Q1 2026. This represents an increase of 120.3% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Apellis Pharmaceuticals, Inc. (APLS) reported on that line in every period on record.
